Business Context and Reporting Period
Company: Grifols, S.A.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Accounting Basis: International Financial Reporting Standards (IFRS)
Reporting Currency: Euro (EUR)
Grifols is a vertically integrated global producer of plasma derivatives, diagnostics, and hospital products. The 2014 reporting period was significantly impacted by the acquisition of the Novartis Diagnostic Business (closed January 9, 2014), which expanded the company's portfolio in transfusion medicine and immunology. The company operates in approximately 100 countries with a direct presence in 28.
Key Financial Metrics
| Metric (in thousands of EUR) | 2014 | 2013 |
|---|---|---|
| Net Revenue | 3,355,384 | 2,741,732 |
| Gross Profit | 1,699,214 | 1,417,852 |
| Gross Margin | 50.6% | 51.7% |
| Operating Result | 857,689 | 736,120 |
| Profit Before Tax | 589,680 | 497,536 |
| Consolidated Profit for the Year | 467,083 | 342,054 |
| Profit Attributable to Parent | 470,253 | 345,551 |
| Basic EPS | 1.37 | 1.01 |
| Cash and Cash Equivalents (Year End) | 1,079,146 | 708,777 |
| Total Debt (Non-current + Current Financial Liabilities) | 4,349,356 | 2,811,355 |
| Net Cash from Operating Activities | 978,928 | 592,011 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 22.4% (24.1% at constant currency) to €3.36 billion. This growth was driven primarily by the Novartis Acquisition (contributing approx. €561 million to the Diagnostic division) and increased sales in the Bioscience division.
- Divisional Performance:
- Bioscience: Revenue increased 2.6% to €2.51 billion (74.9% of total), driven by high volumes in the U.S. and Rest of World.
- Diagnostic: Revenue surged 375.7% to €620 million (18.5% of total) due to the Novartis acquisition.
- Hospital: Revenue decreased 2.4% to €94.8 million due to the termination of a third-party manufacturing contract, partially offset by growth in Spain.
- Profitability: Operating result increased 16.5% to €857.7 million. However, gross margin declined slightly from 51.7% to 50.6% due to the lower margins of the newly acquired Novartis activities.
- Expenses:
- R&D: Increased 46.6% to €180.8 million (5.4% of sales) to accelerate key projects.
- SG&A: Increased 18.3% to €660.8 million, though as a percentage of sales, it decreased to 19.7% due to cost containment.
- Debt and Financing: Total indebtedness increased significantly to approximately €5.4 billion (including €4.9 billion in USD-denominated debt) to finance the Novartis acquisition. The company refinanced existing facilities in February 2014, issuing $1.0 billion in 5.25% Senior Notes due 2022.
Guidance, Outlook, and Risks
Outlook and Capital Expenditures:
- Management expects R&D expenditures to range between 5% and 6% of net revenues in the near term.
- The company is undertaking an investment plan involving cumulative capital expenditures of approximately €600 million from 2014 through 2016, focused on expanding manufacturing facilities (Clayton, Parets, Los Angeles) and plasma collection centers.
- Global sales of plasma derivative products are projected to grow annually at 6% to 8% over the long term.
Key Risks and Contingencies:
- Indebtedness: The company carries substantial debt, which restricts flexibility and requires significant cash flow for interest payments. Covenants limit the ability to pay dividends or incur additional debt.
- Plasma Supply: Revenue growth is dependent on access to U.S. source plasma. Supply constraints or increased costs could materially impact operations.
- Regulatory Environment: Operations are subject to strict FDA and EMA regulations. Non-compliance could lead to facility shutdowns or product recalls. The U.S. Healthcare Reform Law continues to create uncertainty regarding reimbursement rates and rebate obligations.
- Product Liability: Risks associated with plasma-derived products include potential transmission of pathogens and adverse reactions, which could lead to recalls or litigation.
- Foreign Exchange: Approximately 73% of 2014 revenue was denominated in U.S. dollars, exposing the company to significant currency fluctuation risks against the Euro.
Investor Verification Checklist
- Debt Service Coverage: Verify the company's ability to service ~€5.4 billion in debt given the high interest expense (€225 million in 2014) and reliance on operating cash flow.
- Novartis Integration: Assess the long-term margin impact of the Novartis Diagnostic Business, which currently lowers the consolidated gross margin.
- Plasma Collection Capacity: Confirm the status of new plasma collection centers and the ability to meet the projected 7.5 million liters of plasma collection target.
- Reimbursement Trends: Monitor changes in U.S. Medicare/Medicaid reimbursement rates (ASP + 6%) and the impact of the 2% sequestration on net revenue.
- Capital Project Execution: Track the completion and regulatory approval of major capital projects (e.g., new Clayton fractionation plant, Parets expansion) scheduled for 2015-2016.
- Receivables Aging: Review the aging of trade receivables, particularly in Southern Europe (Spain, Italy, Portugal), where government payment delays are common.